.jpg)
Industry Outlook & Insights
Panel Session
Business Strategies
John Babitt
Partner
EY
Charlie Attlan
SVP Business Development
Boston Scientific
Chris Cleary
SVP Business Development
Medtronic
.jpg "Susan Morano photo")
Susan Morano
VP Business Development - Medical Devices
Johnson & Johnson
J.P. Peltier
Global Group Head, Healthcare Investment Banking
Piper Jaffray
Continued strong sector fundamentals, improving end markets and new product launches and healthy pipelines has led to a significant run up in valuations of private and public medtech assets. As a result, organizations have been forced to adopt new and more advanced valuation techniques to appropriately evaluate acquisition targets.
Officials from some of the most successful medtech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive valuation for M&A and what challenges remain, including the following:
• How are companies succeeding in competitive situations for attractive targets?
• What are the right analytical tools for evaluating complex economics globally, including payer dynamics and commercial risks?
• What levels of strategic and operational diligence are required to properly value deal targets?
• How is the capital markets environment—cheap credit, activist shareholders—affecting resource allocation for transformative M&A?
